Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival,
metabolism, and immunity. mTOR is usually assembled into several complexes such as …

Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2–
selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires …

Myeloproliferative neoplasms (MPNs) constitute a group of disorders identified by an
overproduction of cells derived from myeloid lineage. The majority of MPNs have an …

BCR/ABL1–like acute lymphoblastic leukemia (ALL) accounts for 15% to 30% of B‐lineage
ALL, with a peak of incidence occurring in adolescence. This subgroup of patients is …

Acute Lymphoblastic Leukemia (ALL) is an aggressive hematologic disorder and constitutes
approximately 25% of cancer diagnoses among children and teenagers. Pediatric patients …

Patients harboring CRLF2-rearranged B-lineage acute lymphocytic leukemia (B-ALL) face a
5-year survival rate as low as 20%. While significant gains have been made to position …

Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk B-cell Acute
Lymphoblastic Leukemia (B-ALL) characterized by a gene expression profile similar to Ph …

Background Although molecular-targeted agents are still the first choice for advanced
hepatocellular carcinoma (HCC) treatment, the therapeutic efficacy of these agents is not …

Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk
ALL subtype with high rates of relapse and poor patient outcome. Activating mutations …

Children and adults with Philadelphia chromosome–like B cell acute lymphoblastic
leukemia (Ph-like B-ALL) experience high relapse rates despite best-available conventional …